Passive immunotherapeutic strategies for the treatment of malignant gliomas.
Passive immunotherapeutic strategies for the treatment of malignant gliomas.
复制标题
治疗恶性胶质瘤的被动免疫治疗策略。
DOI：
10.1016/j.nec.2012.04.008
复制
发表时间：
2012
影响因子：
2.6
通讯作者：
Yang,Isaac
中科院分区：
文献类型：
--
作者：
Nagasawa,DanielT;Fong,Christina;Yew,Andrew;Spasic,Marko;Garcia,HeatherM;Kruse,CarolA;Yang,Isaac
Malignant gliomas are the most common primary intracranial tumor, with a proclivity for widespread invasion and rampant destruction of healthy parenchyma. This infiltrative process affords high-grade gliomas protection from traditional therapies and subjects the adjacent normal tissue to potential damage from nonspecific treatment modalities. 1, 2 Immunotherapies involving antibodies or sensitized effector cells can offer selective targeting of protein-arbohydrate complexes on tumor cell surfaces that distinguish neoplastic from noncancerous cells. 1, 3 Consequently, the treatment of malignant gliomas may be enhanced not only by increased specificity for tumor tissue but also from decreased toxicity to the host’s healthy cells. 1 This review focuses on published findings from the use of passive immunotherapy for the treatment of high-grade gliomas, particularly glioblastoma multiforme (GBM).
